Evoclin is owned by Mylan.
Evoclin contains Clindamycin Phosphate.
Evoclin has a total of 2 drug patents out of which 0 drug patents have expired.
Evoclin was authorised for market use on 22 October, 2004.
Evoclin is available in aerosol, foam;topical dosage forms.
Evoclin can be used as treatment of acne vulgaris.
The generics of Evoclin are possible to be released after 03 February, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7374747||MYLAN||Pharmaceutical foam|| |
(11 months from now)
|US7141237||MYLAN||Pharmaceutical foam|| |
(a year from now)
Market Authorisation Date: 22 October, 2004
Treatment: Treatment of acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic